Investigation of FCPA Violations in Europe

We represented a Fortune 500 company in the life sciences industry in an investigation by the U.S. Department of Justice and Securities and Exchange Commission of alleged FCPA and local law violations relating to the company’s operations in Europe and conduct of its distributors. This representation included providing guidance and advice about the pros and cons of self-reporting, the potential value of cooperation, and benefits of remedial actions taken to enhance the existing compliance program.

You Also May Be Interested In: